1. Home
  2. Stocks
  3. Blissgvs Share Price

Bliss GVS Pharma Share Price

Pharmaceuticals Small Cap

₹123.49 -0.57 (-0.46%)

05 Nov, 2024 19:22

SIP TrendupStart SIP in BLISSGVS

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹123
  • High
  • ₹126
  • 52 Week Low
  • ₹92
  • 52 Week High
  • ₹150
  • Open Price₹124
  • Previous Close₹124
  • Volume395,163

Investment Returns

  • Over 1 Month -5.2%
  • Over 3 Month + 5.83%
  • Over 6 Month + 3.73%
  • Over 1 Year + 23.12%
SIP Lightning

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.5
  • PEG Ratio
  • -0.7
  • Market Cap Cr
  • 1,300
  • P/B Ratio
  • 1.3
  • Average True Range
  • 7.46
  • EPS
  • 7.2
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -1.27
  • RSI
  • 47.59
  • MFI
  • 62.99

Bliss GVS Pharma Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations182.65148.96163.82161.33171.32
Total Income From Operations182.65148.96163.82161.33171.32
P/L Before Interest, Excpt. Items & Tax27.3427.3227.3830.3147.24
P/L Before Exceptional Items & Tax23.8926.1525.8528.5246.07
P/L After Tax from Ordinary Activities17.0419.42-11.4620.7233.89
Net Profit/Loss For the Period17.0419.42-11.4620.7233.89
IndicatorMar 24Mar 23
Revenue From Operations [Gross]601.98595.59
Revenue From Operations [Net]601.98595.59
Total Operating Revenues605.46598.34
Total Revenue638.96649.11
Total Expenses527.62533.41
Profit/Loss Before Tax70.26115.69
Profit/Loss For The Period50.6485.48
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity125.9243.81
Net Cash Used In Investing Activity-109.59-12.97
Net Cash Used in Finance Activity-20.76-26.05
Net Inc/Dec In Cash And Equivalent-4.434.79
Cash And Equivalent End Of Year14.1718.60
IndicatorMar 24Mar 23
Total Share Capital10.4710.42
Total Non-Current Liabilities46.8049.34
Total Current Liabilities117.31153.36
Total Capital And Liabilities1,152.551,139.69
Total Non-Current Assets379.57410.04
Total Current Assets772.98729.65
Total Assets1,152.551,139.69
Indicator20242023
EBIT Margin (%)19.3421.01
Return On Capital Employed (%)11.3112.74
Return On Equity (%)5.129.12
Long Term Debt To Equity (%)3.554.34
Book Value/Share (INR)94.4289.96
IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations217.68183.64198.13200.72211.88
Total Income From Operations217.68183.64198.13200.72211.88
P/L Before Interest, Excpt. Items & Tax39.5331.6027.1042.1660.58
P/L Before Exceptional Items & Tax35.7130.0725.2540.0459.13
P/L After Tax from Ordinary Activities25.6922.11-4.9129.0743.04
Net Profit/Loss For the Period25.6922.11-4.9129.0743.04
IndicatorMar 24Mar 23
Revenue From Operations [Gross]765.91747.43
Revenue From Operations [Net]765.91747.43
Total Operating Revenues770.24751.59
Total Revenue798.98769.37
Total Expenses652.91663.30
Profit/Loss Before Tax116.87106.07
Profit/Loss For The Period81.5876.73
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity152.4534.31
Net Cash Used In Investing Activity-132.82-7.75
Net Cash Used in Finance Activity-20.89-24.94
Net Inc/Dec In Cash And Equivalent-1.423.02
Cash And Equivalent End Of Year23.5925.01
IndicatorMar 24Mar 23
Total Share Capital10.4710.42
Total Non-Current Liabilities51.0646.17
Total Current Liabilities159.82193.26
Total Capital And Liabilities1,213.871,156.85
Total Non-Current Assets402.25459.49
Total Current Assets811.62697.37
Total Assets1,213.871,156.85
Indicator20242023
EBIT Margin (%)19.8615.49
Return On Capital Employed (%)14.5112.08
Return On Equity (%)7.808.01
Long Term Debt To Equity (%)3.674.60
Book Value/Share (INR)95.8088.08

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹123.49
-0.57 (-0.46%)
pointer
  • stock-down_img
  • Bullish Moving Average 6
  • stock-up_img
  • Bearish Moving Average 10
  • 20 Day
  • ₹125.44
  • 50 Day
  • ₹125.47
  • 100 Day
  • ₹122.48
  • 200 Day
  • ₹117.68

Resistance and Support

124.11 Pivot Speed
  • R3 128.24
  • R2 127.07
  • R1 125.28
  • S1 122.32
  • S2 121.15
  • S3 119.36

Is Bliss GVS Pharma Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities. Bliss Gvs Pharma has an operating revenue of Rs. 800.17 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 15% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -12% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 50 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-07-24 Quarterly Results
2024-05-02 Audited Results & Final Dividend
2024-01-23 Quarterly Results
2023-11-01 Quarterly Results

Bliss GVS Pharma F&O

Bliss GVS Pharma Shareholding Pattern

34.82%
0%
6.56%
12.13%
34.57%
11.92%
  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • Managing Director
  • Mr. Gagan Harsh Sharma
  • ISIN
  • INE416D01022

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹123 As on 05 November, 2024 | 19:08

The Market Cap of Bliss GVS Pharma is ₹1300.4 Cr As on 05 November, 2024 | 19:08

The P/E ratio of Bliss GVS Pharma is 20.5 As on 05 November, 2024 | 19:08

The PB ratio of Bliss GVS Pharma is 1.3 As on 05 November, 2024 | 19:08

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.